SCHEMBL6055321

SCHEMBL6055321

Cc1ccc(S(=O)(=O)OC(OC(C)C)(OC(C)C)[PH2]=O)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.37
ALDH1A1 P00352 4/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
VDR P11473 1/20 0.36
LMNA P02545 3/20 0.35
MAPK1 P28482 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
ESR1 P03372 1/20 0.35
ESR2 Q92731 1/20 0.35
HSP90AA1 P07900 1/20 0.35
MAPT P10636 1/20 0.35
PKM P14618 1/20 0.35
XBP1 P17861 1/20 0.35
MPI P34949 1/20 0.35
HTT P42858 1/20 0.35
RAB9A P51151 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1375600 0.86 ALDH1A1 (0.35) ALDH1A1KMT2ALMNAMAPK1SMN1; SMN2
SCHEMBL904362 0.78 ALDH1A1 (0.40) GAAALDH1A1MEN1KMT2AVDR
SCHEMBL6055317 0.75 GAA (0.37) GAAALDH1A1MEN1KMT2AVDR
SCHEMBL259737 0.73 MMP2 (0.41) GAAALDH1A1MEN1KMT2AVDR
SCHEMBL777187 0.70 GAA (0.50) GAAALDH1A1MEN1KMT2AVDR
SCHEMBL29367126 0.70 GAA (0.50) GAAALDH1A1MEN1KMT2AVDR
SCHEMBL143705 0.70 GAA (0.50) GAAALDH1A1MEN1KMT2AVDR
SCHEMBL14720743 0.69 ALDH1A1 (0.43) GAAALDH1A1MEN1KMT2AVDR
Ammonia Solution, Strong SCHEMBL5917791 0.69 GAA (0.48) GAAALDH1A1MEN1KMT2AVDR
SCHEMBL19949926 0.69 GAA (0.48) GAAALDH1A1MEN1KMT2AVDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1450809-A4 NUCLEOSIDES PREPARATION THEREOF AND USE AS INHIBITORS OF RNA VIRAL POLYMERASES BIOCRYST PHARM INC (US) 2006-07-19 EP disclosed
US-20050033051-A1 Nucleosides preparation thereof and use as inhibitors of rna viral polymerases BIOCRYST PHARMACEUTICALS, INC. 2005-02-10 US disclosed
EP-1450809-A2 NUCLEOSIDES PREPARATION THEREOF AND USE AS INHIBITORS OF RNA VIRAL POLYMERASES Biocryst Pharmaceuticals, Inc. (US) 2004-09-01 EP disclosed
WO-2003087298-A2 NUCLEOSIDES PREPARATION THEREOF AND USE AS INHIBITORS OF RNA VIRAL POLYMERASES BIOCRYST PHARMACEUTICALS, INC. (US) 2003-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050033051-A1 Nucleosides preparation thereof and use as inhibitors of rna viral polymerases NSUN2, RNASEH1, POLR2H GAA 3374/4885ALDH1A1 3040/4885MEN1 3597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.